Appendix 3B
Released
Released
Announcement PDF
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
Appendix 3B
New issue announcement,
application for quotation of additional securities
and agreement
Information or documents not available now must be given to ASX as soon as available. Information and documents
given to ASX become ASX’s property and may be made public.
Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12
Name of entity
Mayne Pharma Group Limited (Company)
ABN
76 115 832 963
We (the entity) give ASX the following information.
Part 1 - All issues
You must complete the relevant sections (attach sheets if there is not enough space).
1
+Class of +securities issued or to be issued
Fully paid ordinary shares in the Company
2
Number of +securities issued or to be
issued (if known) or maximum number
which may be issued
500,000 ordinary shares
3
Principal terms of the +securities (eg, if
options, exercise price and expiry date; if
partly paid +securities, the amount
outstanding and due dates for payment; if
+convertible securities, the conversion
price and dates for conversion)
Fully paid ordinary shares
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 1
4
Do the +securities rank equally in all
respects from the date of allotment with
an existing +class of quoted +securities?
Yes.
If the additional securities do not rank
equally, please state:
the date from which they do
the extent to which they participate
for the next dividend, (in the case of a
trust, distribution) or interest payment
the extent to which they do not rank
equally, other than in relation to the
next dividend, distribution or interest
payment
5
Issue price or consideration
$0.3127 per share
6
Purpose of the issue
(If issued as consideration for the
acquisition of assets, clearly identify those
assets)
Exercise of unlisted options for ordinary shares
6a
Is the entity an +eligible entity that has
obtained security holder approval under
rule 7.1A?
Not applicable.
If Yes, complete sections 6b – 6h in
relation to the +securities the subject of
this Appendix 3B, and comply with section
6i
6b
The date the security holder resolution
under rule 7.1A was passed
Not applicable.
6c
Number of +securities issued without
security holder approval under rule 7.1
Not applicable.
6d
Number of +securities issued with security
holder approval under rule 7.1A
Number of +securities issued with security
holder approval under rule 7.3, or another
specific security holder approval (specify
date of meeting)
Not applicable.
Number of securities issued under an
exception in rule 7.2
Not applicable.
6e
6f
Not applicable.
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 2
6g
If securities issued under rule 7.1A, was
issue price at least 75% of 15 day VWAP as
calculated under rule 7.1A.3? Include the
issue date and both values. Include the
source of the VWAP calculation.
Not applicable.
6h
If securities were issued under rule 7.1A
for non-cash consideration, state date on
which valuation of consideration was
released to ASX Market Announcements
Not applicable.
6i
Calculate the entity’s remaining issue
capacity under rule 7.1 and rule 7.1A –
complete Annexure 1 and release to ASX
Market Announcements
Not applicable.
7
Dates of entering +securities into
uncertificated holdings or despatch of
certificates
7 March 2016
8
Number and +class of all +securities
quoted on ASX (including the securities in
section 2 if applicable)
9
+class of all +securities not
Number and
quoted on ASX (including the securities in
section 2 if applicable)
Number
808,626,346
+Class
Fully paid ordinary shares.
Number
7,500,000
+Class
Employee options pursuant to
CEO Share Option Plan.
Expiring 13 February 2019
exercisable at $0.2435 each.
Employee options pursuant to
Mayne Pharma Employee
Share Option Plan. (Refer
Appendix 1 for further detail)
25,830,000
10
Dividend policy (in the case of a trust,
distribution policy) on the increased
capital (interests)
Not applicable.
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 3
Part 2 - Bonus issue or pro rata issue
11
Is security holder approval required?
Not applicable.
12
Is the issue renounceable or nonrenounceable?
Not applicable.
13
Ratio in which the +securities will be
offered
Not applicable.
14
+Class
Not applicable.
of +securities to which the offer
relates
15
+Record date to determine entitlements
Not applicable.
16
Will holdings on different registers (or
subregisters) be aggregated for calculating
entitlements?
Not applicable.
17
Policy for deciding entitlements in relation
to fractions
Not applicable.
18
Names of countries in which the entity has
+security holders who will not be sent new
issue documents
Not applicable.
Note: Security holders must be told how their entitlements
are to be dealt with.
Cross reference: rule 7.7.
19
Closing date for receipt of acceptances or
renunciations
Not applicable.
20
Names of any underwriters
Not applicable.
21
Amount of any underwriting fee or
commission
Not applicable.
22
Names of any brokers to the issue
Not applicable.
23
Fee or commission payable to the broker
to the issue
Not applicable.
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 4
24
Amount of any handling fee payable to
brokers who lodge acceptances or
renunciations on behalf of +security
holders
Not applicable.
25
If the issue is contingent on +security
holders’ approval, the date of the meeting
Not applicable.
26
Date entitlement and acceptance form
and prospectus or Product Disclosure
Statement will be sent to persons entitled
Not applicable.
27
If the entity has issued options, and the
terms entitle option holders to participate
on exercise, the date on which notices will
be sent to option holders
Not applicable.
28
Date rights
applicable)
(if
Not applicable.
29
Date rights trading will end (if applicable)
Not applicable.
30
How do +security holders sell their
entitlements in full through a broker?
Not applicable.
31
How do +security holders sell part of their
entitlements through a broker and accept
for the balance?
Not applicable.
32
How do +security holders dispose of their
entitlements (except by sale through a
broker)?
Not applicable.
33
+Despatch date
Not applicable.
trading
will
begin
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 5
Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities
34
Type of securities
(tick one)
(a)
Securities described in Part 1
(b)
All other securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee
incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entities that have ticked box 34(a)
Additional securities forming a new class of securities
Tick to indicate you are providing the information or
documents
35
If the +securities are +equity securities, the names of the 20 largest holders of the
additional +securities, and the number and percentage of additional +securities held
by those holders
36
If the +securities are +equity securities, a distribution schedule of the additional
+securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
37
A copy of any trust deed for the additional +securities
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 6
Entities that have ticked box 34(b)
38
Number of securities for which +quotation
is sought
39
Class of +securities for which quotation is
sought
40
Do the +securities rank equally in all
respects from the date of allotment with
an existing +class of quoted +securities?
If the additional securities do not rank
equally, please state:
the date from which they do
the extent to which they participate
for the next dividend, (in the case of a
trust, distribution) or interest payment
the extent to which they do not rank
equally, other than in relation to the
next dividend, distribution or interest
payment
41
Reason for request for quotation now
Example: In the case of restricted securities, end of
restriction period
(if issued upon conversion of another
security, clearly identify that other
security)
Number
42
+class
+Class
+securities
Number and
of all
quoted on ASX (including the securities in
clause 38)
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 7
Quotation agreement
1
+Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the
+securities on any conditions it decides.
2
We warrant the following to ASX.
The issue of the +securities to be quoted complies with the law and is not for an
illegal purpose.
There is no reason why those +securities should not be granted +quotation.
An offer of the securities for sale within 12 months after their issue will not
require disclosure under section 707(3) or section 1012C(6) of the Corporations
Act.
+
Note: An entity may need to obtain appropriate warranties from subscribers for
the securities in order to be able to give this warranty
Section 724 or section 1016E of the Corporations Act does not apply to any
applications received by us in relation to any +securities to be quoted and that noone has any right to return any +securities to be quoted under sections 737, 738
or 1016F of the Corporations Act at the time that we request that the +securities
be quoted.
If we are a trust, we warrant that no person has the right to return the +securities
to be quoted under section 1019B of the Corporations Act at the time that we
request that the +securities be quoted.
3
We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action
or expense arising from or connected with any breach of the warranties in this agreement.
4
We give ASX the information and documents required by this form. If any information or
document not available now, will give it to ASX before +quotation of the +securities begins.
We acknowledge that ASX is relying on the information and documents. We warrant that
they are (will be) true and complete.
Sign here:
............................................................
(Company secretary)
Print name:
Mark Cansdale
Date: 7 March 2016
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 8
MAYNE PHARMA GROUP LIMITED
APPENDIX 1 – EMPLOYEE OPTIONS ISSUED UNDER
EMPLOYEE SHARE OPTION PLAN
Employee options
Expiry date
Exercise Price
Vested
Unvested
12/01/2019
$
0.3127
4,440,000
4,250,000
Total number of shares
issued under option
8,690,000
26/01/2019
$
0.3127
2,440,000
3,800,000
6,240,000
7/03/2019
$
0.3927
800,000
800,000
28/03/2019
$
0.8946
300,000
300,000
600,000
19/06/2019
$
0.8644
120,000
480,000
600,000
30/06/2019
$
0.9131
200,000
800,000
1,000,000
1/07/2019
$
0.4127
200,000
800,000
1,000,000
2/07/2019
$
0.9052
80,000
320,000
400,000
1/08/2019
$
0.8380
200,000
200,000
28/08/2019
$
0.8625
120,000
480,000
600,000
21/10/2019
$
0.6866
80,000
320,000
400,000
11/11/2019
$
0.7590
200,000
800,000
1,000,000
30/11/2019
$
0.7697
200,000
800,000
1,000,000
17/12/2019
$
0.7390
120,000
480,000
600,000
1/02/2020
$
0.6290
Total
540,000
2,160,000
2,700,000
9,040,000
16,790,000
25,830,000
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 9
Share your feedback
Discover